Business Context and Reporting Period
This Form 8-K is filed by Shuttle Pharmaceuticals Holdings, Inc. (SHPH), an emerging growth company, for the reporting period of October 15, 2025. The filing discloses two material events: the entry into a binding term sheet for an asset acquisition and the termination of a material agreement with a primary service provider.
Key Financial Metrics and Material Changes
The filing does not provide standard financial statements, revenue, profit, or cash flow data. However, it discloses specific financial obligations and transaction values:
- Acquisition Commitment: A binding term sheet was signed on October 20, 2025, to purchase substantially all assets and liabilities of 1542770 BC Ltd. ("Molecule") for a total purchase price of $10,000,000.
- Payment Structure: The $10 million consideration will be paid in a combination of cash and common stock, subject to the Company's sole determination and the achievement of certain milestones.
- Outstanding Liability: The Company received a demand for immediate payment of $1.091 million from Theradex Systems, Inc., its primary contract research organization (CRO), following the termination of their master agreement.
Guidance, Outlook, and Material Events
Acquisition of Molecule
The Company entered into a binding term sheet to acquire Molecule. The transaction is subject to customary conditions, including the negotiation of definitive agreements, Board of Directors approval, and completion of due diligence. No closing date or specific milestone details were provided in this filing.
Termination of Theradex Agreement
On October 15, 2025, Theradex Systems, Inc. notified the Company of the termination of their Master Agreement dated November 1, 2018, citing a material breach. Theradex has demanded payment of $1.091 million in outstanding amounts. If payment is not received within 30 days of the notice, Theradex intends to cease providing regulatory and clinical research services.
Risks and Contingencies
- Operational Disruption: The potential cessation of services from the primary CRO (Theradex) poses a risk to ongoing clinical and regulatory activities if the dispute is not resolved within 30 days.
- Liquidity Pressure: The immediate demand for $1.091 million combined with the future cash obligations for the Molecule acquisition may impact liquidity.
- Transaction Uncertainty: The Molecule acquisition is not yet finalized and remains contingent on definitive agreements and due diligence.
Investor Verification Checklist
- Verify the Company's current cash position to assess its ability to meet the $1.091 million demand from Theradex within 30 days.
- Confirm the status of the definitive agreements for the Molecule acquisition and the specific milestones required for payment.
- Assess the impact of losing Theradex as the primary CRO on the Company's clinical trial timelines and regulatory submissions.
- Review the full text of the Binding Term Sheet (Exhibit 10.1) for detailed payment schedules and conditions.